Peter Varunok

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob Lalezari et al. · Hepatology · 2015 · 688 citations · Full text

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Stefan Zeuzem, Ira M. Jacobson, Tolga Baykal et al. · New England Journal of Medicine · 2014 · 514 citations · Full text

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 131 citations · Full text

Difference Between Latiglutenase, Villous Atrophy, Clinical Presentation +3

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine

Jacob Lalezari, J. Greg Sullivan, Peter Varunok et al. · Journal of Hepatology · 2015 · 118 citations · Full text

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

Eric Lawitz, Mihály Makara, Ulus Salih Akarca et al. · Gastroenterology · 2015 · 84 citations · Full text